Search
donislecel-jujn (Lantidra)
Indications:
- islet cell transplantation for adults with diabetes mellitus type 1
Dosage:
- 5000 equivalent islet cells/kg for initial infusion
- 4500 equivalent islet cells/kg for subsequent infusions
- administer cells through the hepatic portal vein
- use with immunosuppression
- do not irradiate
- do not use leukodepleting filters
Adverse effects:
- 90% with >= 1 serious adverse event
- major causes
- infusion procedure
- liver laceration, hemorrhage (13%)
- portal hypertension (9%)
- immunosupression
- infection (87%)
- malignancy (37%)
Mechanism of action:
- allogeneic pancreatic islet cell therapy
General
pancreatic islet cell transplantation
References
- HIGHLIGHTS OF PRESCRIBING INFORMATION
Lantidra - (donislecel-jujn) Allogeneic Pancreatic Islet Cellular Suspension for
hepatic portal vein infusion
https://www.fda.gov/media/169920/download